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Background 
 
Pursuant to 24-A M.R.S. §4302(5), the Superintendent of Insurance must report annually to the 
Joint Standing Committee on Insurance and Financial Services information related to insurance 
claims made for the diagnosis and treatment of Lyme disease and other tick-borne illnesses for 
all covered individuals in the State of Maine.  This report covers calendar year 2017.     
 
Included within this report is data about the number of claims made for the diagnosis and 
treatment of Lyme disease and other tick-borne illnesses; the number of claim denials and 
reasons for those denials; the number and outcome of internal appeals; the total dollar 
amounts of those claims; and the number of external appeals related to the treatment of Lyme 
disease and other tick-borne illnesses. 
 
The Maine Center for Disease Control and Prevention identified five kinds of reported tick-
borne illnesses in Maine:  Lyme disease, Babesiosis, Ehrlichiosis (Anaplasmosis), Rocky 
Mountain Spotted Fever, and Powassan virus.  Insurance carriers licensed to write health 
insurance coverage in Maine are required to report claims information for all five tick-borne 
illnesses to the Bureau of Insurance.  
 
Data is collected via an online reporting form and includes claims for all insured Maine 
residents; however, the data does not include MaineCare or Medicare claims.  Respondents 
include active insurers with authority to write health insurance in Maine.  There was a 100% 
response rate from insurers.  
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Tick-Borne Illness Claims by Category 
 
Table 1 shows the number of claims submitted, paid and denied by category of tick-borne 
illness, as well as the total amount paid for claims.  The reported data includes claims made for 
the diagnosis and treatment of tick-borne illnesses for covered individuals in Maine in 2017.  
Five categories of tick-borne illnesses are listed based upon the International Classification of 
Diseases (ICD-10 codes). 
 
The figures in Table 1 represent the number of claims reported, not the number of enrollees 
with a tick-borne illness.  One enrollee may have several claims within the calendar year 
relating to a tick-borne illness.  The “Percentage of Claims Paid” column is calculated by dividing 
the number of claims paid for a category (e.g., Lyme) by the number of claims submitted for 
that category. 
 
Table 1.  Tick-Borne Illness Claims by Category, 2017 
Category Submitted Paid Denied 
Percentage of 
Claims Paid 
Total Paid 
Babesiosis 780 696 84 89.23% $109,299.61 
Ehrlichiosis 
(Anaplasmosis) 
339 322 17 94.99% $179,475.94 
Lyme disease 10,389 9,386 1,003 90.35% $1,304,897.91 
Powassan virus 19 16 3 84.21% $4,601.42 
Rocky 
Mountain 
Spotted Fever 
46 42 4 91.30% $1,434.79 
Total: 11,573 10,462 1,111 90.40% $ 1,599,709.67 
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Reasons for Denied Tick-Borne Illness Claims 
 
Table 2 provides the reasons given for denied claims related to any treatment for tick-borne 
illnesses.  A claim may have multiple reasons for denial.  The top three reasons for denial were 
Incorrect Coding, Not a Covered Benefit, and Duplicate Claim. 
 
Table 2.  Reasons for Denied Tick-Borne Illness Claims, 2017 
 
 
Reasons for Denial 
Number of  
Denied Claims 
Incorrect Coding 180 
Not a Covered Benefit 131 
Duplicate Claim 112 
No Pre-Authorization 110 
Coverage Terminated 74 
More Information Requested/Not Received 36 
Not Medically Necessary 32 
Maximum Benefits Exceeded 14 
Non-Participating Provider 11 
Pre-existing Conditions Exclusion 2 
Considered Experimental/Investigational 0 
Other Reasons for Denial 410 
Total: 1,112 
 
Appeals/Reconsiderations/External Reviews for All Tick-Borne Illnesses 
 
Table 3 provides the number of appeals and reconsiderations that were conducted by the 
insurance companies reporting data to the Bureau of Insurance.  The Bureau had no requests 
for an independent external review relating to tick-borne illnesses in 2017. 
 
Table 3.  Number of Appeals/Reconsiderations and External Reviews for  
All Tick-Borne Illnesses, 2017 
 Upheld Overturned Other Total 
Appeals/Reconsideration (Internal) 0 0 0 0 
Independent External Reviews  
 
0 0 0 0 
Total: 0 0 0 0 
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Lyme Disease Claims by Treatment Type 
 
Table 4 shows the number of Lyme disease claims by type of treatment provided for covered 
individuals.  Claims for antibiotic treatment by any means of administration are included. 
 
The “Percentage of Claims Paid” column is calculated by dividing the number of claims paid for 
a treatment type by the number of claims submitted for that treatment type.  It is possible for 
information about one enrollee to be entered in more than one category.  For example, an 
enrollee could have paid claims for antibiotics and have paid claims for other types of 
treatment, such as physical therapy. 
 
Table 4.  Lyme Disease Claims by Treatment Type, 2017 
 
Treatment Type Submitted Paid 
Percentage 
of Claims 
Paid 
Denied Total Paid 
Antibiotic Treatment 2,363 2,316 98.01% 47 $196,117.06 
Other Treatment 10,395 9,408 90.51% 987 $1,522,672.00 
Total: 12,758 11,724 91.90% 1,034 $1,718,789.06 
 
